Alecensa is a highly selective, central nervous system-active, oral medicine used for the treatment of people with non-small cell lung cancer (NSCLC) whose tumours are identified as anaplastic lymphoma kinase (ALK)-positive. Alecensa is a tyrosine kinase inhibitor that targets ALK fusion proteins, preventing signalling within cancer cells to inhibit their growth and survival.

Alecensa is currently approved in over 80 countries as a first-line treatment for advanced (metastatic) ALK-positive NSCLC. It is also approved in over 90 countries for the treatment of ALK-positive advanced NSCLC patients whose disease has worsened after, or who could not tolerate treatment with, crizotinib.

M-PK-00001196